2017 30TH PROCEEDINGS OF NAVDF April 26-29, 2017 ORLANDO, FLORIDA 2 (orfenicol, terbinane, mometasone furoate) Otic Solution Antibacterial, antifungal, and anti-inammatory For Otic Use in Dogs Only The following information is a summary of the complete product information and is not comprehensive. Please refer to the approved product label for complete product information prior to use. CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. PRODUCT DESCRIPTION: CLARO® contains 16.6 mg/mL orfenicol, 14.8 mg/mL terbinane (equivalent to 16.6 mg/mL terbinane hydrochloride) and 2.2 mg/mL mometasone furoate. Inactive ingredients include puried water, propylene carbonate, propylene glycol, ethyl alcohol, and polyethylene glycol. INDICATIONS: CLARO® is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius). DOSAGE AND ADMINISTRATION: CLARO® should be administered by veterinary personnel. Administration is one dose (1 dropperette) per aected ear. The duration of eect should last 30 days. Clean and dry the external ear canal before administering the product. Verify the tympanic membrane is intact prior to administration. Cleaning the ear after dosing may aect product eectiveness. Refer to product label for complete directions for use. CONTRAINDICATIONS: Do not use in dogs with known tympanic membrane perforation (see PRECAUTIONS). CLARO® is contraindicated in dogs with known or suspected hypersensitivity to orfenicol, terbinane hydrochloride, or mometasone furoate, the inactive ingredients listed above, or similar drugs, or any ingredient in these medicines. WARNINGS: Human Warnings: Not for use in humans. Keep this and all drugs out of reach of children. In case of accidental ingestion by humans, contact a physician immediately. In case of accidental skin contact, wash area thoroughly with water. Avoid contact with eyes. Humans with known hypersensitivity to orfenicol, terbinane hydrochloride, or mometasone furoate should not handle this product. PRECAUTIONS: Do not administer orally. The use of CLARO® in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membrane should be conrmed before administering the product. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs. Use with caution in dogs with impaired hepatic function. The safe use of CLARO® in dogs used for breeding purposes, during pregnancy, or in lactating bitches has not been evaluated. ADVERSE REACTIONS: In a eld study conducted in the United States, there were no directly attributable adverse reactions in 146 dogs administered CLARO®. To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, contact Bayer HealthCare at 1-800-422-9874. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth. NADA 141-440, Approved by FDA. Bayer, the Bayer Cross and CLARO are registered trademarks of Bayer. ©2016 Bayer HealthCare, LLC. Distributed by: Bayer HealthCare LLC, Animal Health Division, Shawnee Mission, Kansas 66201 • World-renowned Speakers • Exceptional Round Table Topics and Discussions • Informative Poster Displays • Industry Exhibitors • Lively Receptions • Two half days to allow for free time • And much, much, more in store For more information about North American Veterinary Dermatology Forum 2018, consult our website at navdf.org or call 1-866-854-5525 #NAVDF2018 NAVDF 2019 April 10-13 HILTON AUSTIN TABLE OF CONTENTS GENERAL INFORMATION ABSTRACTS Dex Game 7 THURSDAY 22 App 7 Residents’ Short Communications 22 Shuttle Schedule 8 Clinical Short Communications 23 A la Carte Lunch 8 Scientific Session Presentations 23 Hotel Map 9 Concurrent Session Presentations 23 Registration Hour 10 FRIDAY 91 Exhibit Hall Hours 10 Original Short Communications 91 Poster Hours 10 Clinical Short Communications 91 Exhibit Hall Map 10 Original and Clinical Short Communications 92 COMPLETE SCHEDULE Scientific Session Presentations 92 Wednesday 13 Concurrent Session Presentations 92 Thursday 14 SATURDAY 142 Friday 16 Scientific Session Presentations 142 Saturday 18 Concurrent Session Presentations 142 ISVD Sessions 143 ROUNDTABLE SESSIONS ADVT Sessions 143 Thursday 20 POSTERS 206 Friday 20 Saturday 20 6 LOSTLOST DOG DOG Dex disappeared from his dog house! Please keep an eye out for him around the conference. If you spot him make sure to snap a photo and share it on the app using your Instagram account. Remember to tag the NAVDF (@NAVDF) and use the hashtag #detectDex. Once your photo is shared, return Dex to his dog house at NAVDF registration and claim your reward! App Download Instructions 1. Search NAVDF in App Store 2. Click "GET" to download 1. Search NAVDF in Google Play 2. Click “Install” to download LAPTOP OR Use https://crowd.cc/2017navdf OTHER DEVICES for online version of the app 7 SHUTTLE SCHEDULE Shuttle from Animal Kingdom Lodge to Contemporary: Wednesday: 3:30 pm – 8:30 pm Thursday: 6:30 am – 6:30 pm Friday: 6:30 am – 4:30 pm Saturday: 6:30 am – 6:30 pm The shuttle will run bottom of each hour (:30) pick up/ drop off at Animal Kingdom odgeL and top of each hour (:00) pick up/ drop off at the Contemporary. Local Taxi Companies: Diamond Cab Company : 407-523-3333 Taxi Orlando Cab Service: 321-732-8266 Visit Disney's Yellow Cab Orlando: 407-900-5207 Magical Express for complimentary App Cars: transportation to and Uber from the airport. Lyft A LA CARTE LUNCH A la Carte Lunch 12:30 – 2:30 pm Visit Disney Dining for all the options on Disney Properties: https://disneyworld.disney.go.com/dining/ Ala Carte Lunches will be available at the Contemporary in the Convention Porte Cochere area during the lunch break time period. All seating is outside under the Porte Cochere. 8 HOTELDISNEY’S CONTEMPORARY MEETING RESORT –SPACE MAIN LEVEL Sorcerer’s Apprentice Lobby Sorcerer’s Sorcerer’s Apprentice Ballroom Apprentice Courtyard ©Disney 9 REGISTRATION & EXHIBIT HALL HOURS REGISTRATION HOURS Wednesday, April 26 5:00pm - 7:00pm Thursday, April 27 7:00am - 5:30pm Friday, April 28 7:30am - 5:30pm Saturday, April 29 7:30am - 5:30pm EXHIBIT HALL & POSTER HOURS Thursday, April 27 8:30am - 4:30pm Friday, April 28 8:30am - 3:30pm Saturday, April 29 8:30am - 11:30am 10 11 Baytril® Otic (enrofloxacin/silver sulfadiazine) Antibacterial-Antimycotic Emulsion For Ototopical Use In Dogs Caution: Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals. PRODUCT DESCRIPTION: Each milliliter of Baytril® Otic contains: enrofloxacin 5 mg (0.5% w/v), silver sulfadiazine (SSD) 10 mg (1.0% w/v), benzyl alcohol (as a preservative) and cetylstearyl alcohol (as a stabilizer) in a neutral oil and purified water emulsion. The active ingredients are delivered via a physiological carrier (a nonirritating emulsion). MICROBIOLOGY: In clinical field trials, Baytril® Otic demonstrated elimination or reduction of clinical signs associated with otitis externa and in vitro activity against cultured organisms. Baytril® Otic is effective when used as a treatment for canine otitis externa associated with one or more of the following organisms: Malassezia pachydermatis, coagulase-positive Staphylococcus spp., Pseudomonas aeruginosa, Enterobacter spp., Proteus mirabilis, Streptococci spp., Aeromonas hydrophila, Aspergillus spp., Klebsiella pneumoniae, and Candida albicans. INDICATIONS: Baytril® Otic is indicated as a treatment for canine otitis externa complicated by bacterial and fungal organisms susceptible to enrofloxacin and/or silver sulfadiazine (see Microbiology section). EFFECTIVENESS: Due to its combination of active ingredients, Baytril® Otic provides antimicrobial therapy against bacteria and fungi (which includes yeast) commonly encountered in cases of canine otitis externa. CONTRAINDICATIONS: Baytril® Otic is contraindicated in dogs with suspected or known hypersensitivity to quinolones and/or sulfonamides. HUMAN WARNINGS: Not for human use. Keep out of the reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation develops or persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolone compounds or antibacterials should avoid handling this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. PRECAUTIONS: The use of Baytril® Otic in dogs with perforated tympanic membranes has not been evaluated. Therefore, the integrity of the tympanic membrane should be evaluated before administering this product. If hearing or vestibular dysfunction is noted during the course of treatment, discontinue use of Baytril® Otic. Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with